# An Exploratory Clinical Study Evaluating the Safety and Efficacy of Intravenous Anti-CD20/CD30-CAR-T Cell Infusion in Relapsed/Refractory Lymphoma Patients.

> **NCT06519344** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Shanghai Tongji Hospital, Tongji University School of Medicine** · enrollment: 12 (estimated)

## Conditions studied

- B Cell Malignancies

## Interventions

- **BIOLOGICAL:** anti-CD20/CD30-CAR-T Cells

## Key facts

- **NCT ID:** NCT06519344
- **Lead sponsor:** Shanghai Tongji Hospital, Tongji University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07-31
- **Primary completion:** 2026-07-30
- **Final completion:** 2027-07-30
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2024-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06519344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06519344, "An Exploratory Clinical Study Evaluating the Safety and Efficacy of Intravenous Anti-CD20/CD30-CAR-T Cell Infusion in Relapsed/Refractory Lymphoma Patients.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06519344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*